Hepatic CT perfusion CT for the therapeutic response of sorafenib for hepatocellular carcinoma

Hepatic CT perfusion CT for the therapeutic response of sorafenib for hepatocellular carcinoma - Hepatic CT perfusion CT for the therapeutic response of sorafenib for hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011522

Enrollment

Registered

2013-08-19

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Patients with hepatocellular carcinoma who are scheduled for sorafenib therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (a) Patients who are older than 20 year-old (b) Patients with hepatocellular carcinoma who are scheduled for sorafenib therapy (c) Patients who weigh less than 100kg (d) Patients with consent for this study

Exclusion criteria

Exclusion criteria: (a) Patients who have allergy to CT contrast media (b) Patients whose performance status is severe (c) Patients with bronchial asthma (d) Patients with severe renal dysfunction (eGFR lower than 30ml/min/1.73m2) (e) Patients who are pregnant or lactating patients (f) Patients whom doctor in charge has decided to be inappropriate for this study

Design outcomes

Primary

Measure	Time frame
To determine clinical utility of hepatic CT perfusion	—

Countries

Japan

Contacts

Public ContactYuko Nakamura

Hiroshima University Diagnostic Radiology

yukon@hiroshima-u.ac.jp082-257-5257

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026